De novo belatacept in clinical vascularized composite allotransplantation.

Most immunosuppressive regimens used in clinical vascularized composite allotransplantation (VCA) have been calcineurin inhibitor (CNI)-based. As such, most recipients have experienced CNI-related side effects. Costimulation blockade, specifically CD28/B7 inhibition with belatacept, has emerged as a clinical replacement for CNI-based immunosuppression in kidney transplantation. We have previously shown that belatacept can be used as a centerpiece immunosuppressant for VCA in nonhuman primates, and subsequently reported successful conversion from a CNI-based regimen to a belatacept-based regimen after clinical hand transplantation. We now report on the case of a hand transplant recipient, whom we have successfully treated with a de novo belatacept-based regimen, transitioned to a CNI-free regimen. This case demonstrates that belatacept can provide sufficient prophylaxis from rejection without chronic CNI-associated side effects, a particularly important goal in nonlifesaving solid organ transplants such as VCA.

Duke Scholars

Author Linda Carime Cendales Surgery, Plastic, Maxillofacial, and Oral Surgery

Author David Simms Ruch Orthopaedic Surgery

Author Adela Rambi Guanco Cardones Dermatology

Author Guy Glenn Potter Psychiatry & Behavioral Sciences, Adult Psychiatry & Psychol ...

Author Joshua Ryan Dooley Anesthesiology, Regional

Author Dongfeng Chen Pathology

Author Maria Angelica Selim Pathology

Author Allan Douglas Kirk Surgery, Abdominal Transplant Surgery